MOLECULAR PARTNERS ADS/1 (F:6ML0) — Stock Price
MOLECULAR PARTNERS ADS/1 (F:6ML0) is currently trading at €3.54 EUR, down 3.80% today. Over the past 52 weeks, shares have ranged between €2.88 and €4.20. This page tracks MOLECULAR PARTNERS ADS/1's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see cash flow conversion of MOLECULAR PARTNERS ADS/1.
MOLECULAR PARTNERS ADS/1 (6ML0) Stock Price Chart — Daily History & Trading Volume
The chart below tracks MOLECULAR PARTNERS ADS/1's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
MOLECULAR PARTNERS ADS/1 Income Statement — Revenue, Profit & Earnings by Year
MOLECULAR PARTNERS ADS/1's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €0.00 | €4.97 Million | €7.04 Million | €189.56 Million | €9.33 Million |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Research & Development | €40.19 Million | €48.60 Million | €48.78 Million | €50.75 Million | €55.72 Million |
| SG&A | €14.87 Million | €17.16 Million | €19.00 Million | €21.82 Million | €16.91 Million |
| Total Operating Expenses | €55.44 Million | €66.19 Million | €68.15 Million | €72.94 Million | €72.75 Million |
| Operating Income | €-55.44 Million | €-61.22 Million | €-61.11 Million | €116.61 Million | €-63.42 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €18.00K | €25.00K | €34.00K | €605.00K | €548.00K |
| Income Before Tax | €-61.65 Million | €-54.04 Million | €-61.98 Million | €117.85 Million | €-63.78 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-61.65 Million | €-54.04 Million | €-61.98 Million | €117.85 Million | €-63.78 Million |
MOLECULAR PARTNERS ADS/1 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes MOLECULAR PARTNERS ADS/1's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €102.11 Million | €158.53 Million | €198.35 Million | €262.26 Million | €172.67 Million |
| Total Current Assets | €96.88 Million | €154.28 Million | €192.46 Million | €254.75 Million | €164.19 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €10.40 Million | €85.56 Million | €119.58 Million | €161.20 Million | €61.00 Million |
| Net Receivables | €253.00K | €286.00K | €295.00K | €521.00K | €23.71 Million |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €21.77 Million | €16.89 Million | €21.92 Million | €27.09 Million | €65.38 Million |
| Total Current Liabilities | €11.03 Million | €10.79 Million | €14.42 Million | €17.25 Million | €46.87 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | €80.33 Million | €141.64 Million | €176.43 Million | €235.17 Million | €107.29 Million |
| Retained Earnings | €-311.75 Million | €-246.29 Million | €-191.75 Million | €-127.78 Million | €-250.95 Million |
MOLECULAR PARTNERS ADS/1 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how MOLECULAR PARTNERS ADS/1 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-51.26 Million | €-59.25 Million | €-59.01 Million | €118.57 Million | €-90.95 Million |
| Capital Expenditures | €714.00K | €723.00K | €808.00K | €1.42 Million | €1.31 Million |
| Free Cash Flow | €-51.97 Million | €-59.97 Million | €-59.81 Million | €117.15 Million | €-92.26 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | €-1.15 Million | €14.43 Million | €-1.17 Million | €-1.57 Million | €50.58 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €4.42 Million | €4.11 Million | €5.21 Million | €5.09 Million | €4.08 Million |
| Depreciation | €2.14 Million | €2.37 Million | €2.42 Million | €2.39 Million | €2.56 Million |
| Change in Cash | €18.78 Million | €-3.44 Million | €-20.64 Million | €16.13 Million | €-61.91 Million |
MOLECULAR PARTNERS ADS/1 Earnings History — EPS Actual vs. Analyst Estimates
Track MOLECULAR PARTNERS ADS/1's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 15, 2027 | — | — | — |
| Aug 25, 2026 | — | — | — |
| Mar 12, 2026 | — | — | — |
| Aug 25, 2025 | — | — | — |
| Apr 17, 2025 | — | — | — |
| Mar 06, 2025 | — | — | — |
| Nov 01, 2024 | — | — | — |